425 related articles for article (PubMed ID: 27647569)
1. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
Michels GM; Ramsey DS; Walsh KF; Martinon OM; Mahabir SP; Hoevers JD; Walters RR; Dunham SA
Vet Dermatol; 2016 Dec; 27(6):478-e129. PubMed ID: 27647569
[TBL] [Abstract][Full Text] [Related]
2. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis.
Michels GM; Walsh KF; Kryda KA; Mahabir SP; Walters RR; Hoevers JD; Martinon OM
Vet Dermatol; 2016 Dec; 27(6):505-e136. PubMed ID: 27647513
[TBL] [Abstract][Full Text] [Related]
3. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.
Moyaert H; Van Brussel L; Borowski S; Escalada M; Mahabir SP; Walters RR; Stegemann MR
Vet Dermatol; 2017 Dec; 28(6):593-e145. PubMed ID: 28906040
[TBL] [Abstract][Full Text] [Related]
4. Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab.
Calesso JR; Marques VS; de Carvalho OV; Costa-Val AP
Pol J Vet Sci; 2023 Jun; 26(2):231-238. PubMed ID: 37389418
[TBL] [Abstract][Full Text] [Related]
5. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
[TBL] [Abstract][Full Text] [Related]
6. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
Cosgrove SB; Wren JA; Cleaver DM; Walsh KF; Follis SI; King VI; Tena JK; Stegemann MR
Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA.
Souza CP; Rosychuk RAW; Contreras ET; Schissler JR; Simpson AC
Vet Dermatol; 2018 Dec; 29(6):489-e164. PubMed ID: 30141223
[TBL] [Abstract][Full Text] [Related]
8. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs.
Marsella R; Ahrens K; Wilkes R; Trujillo A; Dorr M
Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565
[TBL] [Abstract][Full Text] [Related]
9. A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis.
Van Brussel L; Moyaert H; Escalada M; Mahabir SP; Stegemann MR
Vet Dermatol; 2021 Oct; 32(5):477-e131. PubMed ID: 34180084
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study to evaluate the effect of EFF1001, an Actinidia arguta (hardy kiwi) preparation, on CADESI score and pruritus in dogs with mild to moderate atopic dermatitis.
Marsella R; Messinger L; Zabel S; Rosychuck R; Griffin C; Cronin PO; Belofsky G; Lindemann J; Stull D
Vet Dermatol; 2010 Feb; 21(1):50-7. PubMed ID: 19843302
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial.
Nuttall T; Mueller R; Bensignor E; Verde M; Noli C; Schmidt V; Rème C
Vet Dermatol; 2009 Jun; 20(3):191-8. PubMed ID: 19374721
[TBL] [Abstract][Full Text] [Related]
12. The glucocorticoid sparing efficacy of Phytopica in the management of canine atopic dermatitis.
Schmidt V; McEwan N; Volk A; Helps J; Morrell K; Nuttall T
Vet Dermatol; 2010 Feb; 21(1):96-105. PubMed ID: 20187915
[TBL] [Abstract][Full Text] [Related]
13. Hair cortisol concentration, disease severity and quality of life in dogs with atopic dermatitis during lokivetmab therapy.
Stuart Marques V; Calesso JR; de Carvalho OV; da Costa-Val Bicalho AP
Vet Dermatol; 2023 Aug; 34(4):339-347. PubMed ID: 37165693
[TBL] [Abstract][Full Text] [Related]
14. Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus.
Fleck TJ; Norris LR; Mahabir S; Walters RR; Martinon O; Dunham SA; Gonzales AJ
Vet Dermatol; 2021 Dec; 32(6):681-e182. PubMed ID: 33830571
[TBL] [Abstract][Full Text] [Related]
15. The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis.
Szczepanik M; Wilkołek P; Gołyński M; Sitkowski W; Taszkun I; Toczek W
Vet Dermatol; 2019 Aug; 30(4):330-e93. PubMed ID: 31090122
[TBL] [Abstract][Full Text] [Related]
16. Weekly topical therapy based on plant extracts combined with lokivetmab in canine atopic dermatitis.
Bensignor E; Videmont E
Vet Dermatol; 2022 Feb; 33(1):68-e22. PubMed ID: 34414621
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial.
Olivry T; Rivierre C; Jackson HA; Murphy KM; Davidson G; Sousa CA
Vet Dermatol; 2002 Apr; 13(2):77-87. PubMed ID: 11972891
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study.
van Amersfort K; Vernooij JCM; van der Lee A
Vet Dermatol; 2023 Oct; 34(5):373-384. PubMed ID: 37186491
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blinded, placebo-controlled pilot study on the effects of topical blackcurrant emulsion enriched in essential fatty acids, ceramides and 18-beta glycyrrhetinic acid on clinical signs and skin barrier function in dogs with atopic dermatitis.
Marsella R; Cornegliani L; Ozmen I; Bohannon M; Ahrens K; Santoro D
Vet Dermatol; 2017 Dec; 28(6):577-e140. PubMed ID: 28736984
[TBL] [Abstract][Full Text] [Related]
20. Tepoxalin reduces pruritus and modified CADESI-01 scores in dogs with atopic dermatitis: a prospective, randomized, double-blinded, placebo-controlled, cross-over study.
Horvath-Ungerboeck C; Thoday KL; Shaw DJ; van den Broek AH
Vet Dermatol; 2009 Aug; 20(4):233-42. PubMed ID: 19552701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
